RARE
$21.60
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, E...
Recent News
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study
Ultragenyx Pharmaceutical reports phase III success for DTX301 in OTC deficiency, lowering ammonia 18% compared to placebo and keeping levels normal through 36 weeks.
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure
Evotec will cut 800 employees in its second layoff round since 2024. Elsewhere, Ultragenyx got a needed win and a twice-rejected cell therapy is getting an audience at the FDA.
Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Volatility
Ultragenyx Pharmaceutical overview Ultragenyx Pharmaceutical (RARE) has been drawing investor attention after recent trading that left the share price at $23.04, with performance over the past month and past 3 months reflecting ongoing volatility in sentiment. See our latest analysis for Ultragenyx Pharmaceutical. Recent trading has been choppy, with a 1-day share price return of 0.57% and a 7-day gain of 1.41%. However, a 90-day share price decline of 33.7% and a 1-year total shareholder...
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutical Inc.’s share was trading at $23.88 as of February 9th. Ultragenyx Pharmaceuticals positions itself as a diversified rare disease company with four approved products generating approximately $670 million in […]
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)
Ultragenyx Pharmaceutical (NASDAQ:RARE) is one of the 17 biotechnology stocks with more than 50% upside. On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, who maintained a Buy rating on the stock. The analyst’s estimate leads to a promising upside potential of more than […]